Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Nader Kabbani, who led the technology giant’s acquisition of PillPack and the launch of Amazon Pharmacy, will take the chief ...

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Novo Nordisk's obesity sales grew 55% to reach DKK 8.4 billion ($1.2 billion) last year, led by Wegovy with a supporting role for older, once-daily injectable Saxenda (liraglutide).